For those newly infected and diagnosed with HIV in Canada, if they seek treatment right away, the long-term outlook is quite different than it used to be. “The news is very good compared to 20 years ago…a young person diagnosed with HIV today, a young adult, who begins therapy shortly thereafter and takes therapy every […]
HIV rates still rising in Canada, but treatment is simpler, safer and effective Read More »
Ontario is nearing United Nations targets set to ensure an international standard of HIV treatment and to bring about the end of the AIDS epidemic, a new study suggests. But some suffering from the disease are still falling through gaps in care, the study says. Last year, the UN introduced its 90-90-90 strategy. The goal
Study shows Ontario nearing UN AIDS targets Read More »
A new study from the Canadian Observational Cohort (CANOC) Collaboration, housed at the BC Centre for Excellence in HIV/AIDS (BC-CfE), finds the overall life expectancy of people living with HIV who have initiated antiretroviral therapy (ART) is 65 years of age.
Study: Life Expectancy of People Living with HIV in Canada Now Reaches 65 Years of Age Read More »
People who switch away from their initial antiretroviral therapy (ART) regimen when their viral load is undetectable may have a higher likelihood of subsequent virological failure, researchers reported at the 20th International AIDS Conference last week in Melbourne. However, the association varied across groups and the researchers suggested their findings may reflect issues such as
Switching from first-line ART with suppressed viral load linked to treatment failure Read More »
Canadians coinfected with HIV and hepatitis C virus (HCV) had a worse response to antiretroviral therapy (ART) and a higher death rate if they had an injection drug use (IDU) history. The findings could clarify understanding of how HCV affects HIV infection. CANOC Collaboration investigators observed that worse clinical outcomes seen in HIV/HCV-coinfected people may
DISENTANGLING IDU AND HCV IMPACTS ON HIV OUTCOMES IN CANADIANS Read More »
A collaboration of researchers is studying a comprehensive dataset of over 8,000 people on antiretroviral HIV therapies to assess how Canada is dealing with the HIV/AIDS epidemic. A Canadian living with the human immunodeficiency virus (HIV) is most likely to achieve “viral suppression” if they are male, reside in Ontario and have no history of
Research Profile – Going Non-Viral: Achieving HIV Suppression Read More »
Results will help develop effective prevention and HIV management programs Vancouver, British Columbia (May 19, 2010) – Researchers from British Columbia, Ontario and Quebec revealed findings from a new national study today that showed HIV risk factors and clinical indicators for Canadian women vary significantly among provinces. Researchers affiliated with the Canadian Observational Cohort (CANOC),
During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.
During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service
The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below
